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Abstract
Background: It is no longer adequate to choose reference genes blindly. We present the first study that
defines the suitability of 12 reference genes commonly used in cancer studies (ACT, ALAS, B2M, GAPDH,
HMBS, HPRT, KALPHA, RPS18, RPL27, RPS29, SHAD and  TBP) for the normalization of quantitative
expression data in the field of head and neck squamous cell carcinoma (HNSCC).
Results: Raw expression levels were measured by RT-qPCR in HNSCC and normal matched mucosa of
46 patients. We analyzed the expression stability using geNorm and NormFinder and compared the
expression levels between subgroups. In HNSCC and/or normal mucosa, the four best normalization
genes were ALAS, GAPDH, RPS18 and SHAD and the most stable combination of two genes was GAPDH-
SHAD. We recommend using KALPHA-TBP for the study of T1T2 tumors, RPL27-SHAD for T3T4 tumors,
KALPHA-SHAD for N0 tumors, and ALAS-TBP for N+ tumors. ACT, B2M, GAPDH, HMBS, HPRT, KALPHA,
RPS18, RPS29, SHAD and TBP were slightly misregulated (<1.7-fold) between tumor and normal mucosa
but can be used for normalization, depending on the resolution required for the assay.
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Conclusion: In the field of HNSCC, this study will guide researchers in selecting the most appropriate
reference genes from among 12 potentially suitable reference genes, depending on the specific setting of
their experiments.
Background
RT-qPCR is a simple, fast, cost-effective and sensitive tech-
nique that has been extensively used in cancer research. In
the field of head and neck squamous cell carcinoma
(HNSCC), RT-qPCR has mainly been used to identify
gene regulation in tissue from the upper aerodigestive
tract induced by conditions such as cancer or drug, alco-
hol and tobacco use. From a clinical point of view, this
approach aims to discover transcriptional alterations that
can be used for diagnosis, classification and/or prognosis
[1]. Among the pitfalls of this measuring tool, the normal-
ization step is certainly one of the most debated [2]. RT-
qPCR normalization procedures have been developed in
order to minimize inter-sample variability due to techni-
cal artifacts such as flaws in RNA concentration assess-
ment or the handling process, as well as variable retro-
transcription efficiency [3,4]. The vast majority of RT-
qPCR studies rely on the measurement of internal control
genes, called housekeeping genes or reference genes,
simultaneously with the genes of interest. Since the refer-
ence genes are exposed to the same preparation steps as
the genes of interest, this normalization adjusts for differ-
ences in amount and quality of starting material [5]. A
perfect reference gene should have a steady expression in
different tested tissues and should not be regulated by
physiological or pathological mechanisms or by external
causes. Unfortunately, it has been clearly demonstrated
that a universal reference gene does not exist and that even
housekeeping gene expression can be influenced by cellu-
lar processes like differentiation, cell cycle, and cancer
progression, or modulated by external factors such as
drugs, radiotherapy and hormonal changes [6-9]. Despite
this evidence, which highlights the importance of validat-
ing a potential reference gene for each specific experimen-
tal condition, most RT-qPCR studies employ arbitrarily
selected endogenous genes without proper validation of
their presumed stability of expression. This negligence
could lead to systematic false measurements and, conse-
quently, to erroneous conclusions [3,10].
The systematic study of the suitability of reference genes
for RT-qPCR normalization in the field of HNSCC has
thus far been lacking. We thus aimed to test the appropri-
ateness of 12 commonly used reference genes (ACT,
ALAS, B2M, GAPDH, HMBS, HPRT, KALPHA, RPS18,
RPL27, RPS29, SHAD and TBP) for RT-qPCR normaliza-
tion. We evaluated their expression stability in HNSCC
and matched normal mucosa and we looked at potential
differential regulation between clinically relevant sub-
groups (tumor versus normal mucosa, T1T2 versus T2T3
stages, N0 versus N+ stage). Because the use of at least two
reference genes is recommended, we indicate for each tis-
sue subgroup the best combination of two genes that
should be privileged [11].
Results
Raw Cp values of reference genes
The median expression range of the 12 tested genes was
calculated from raw Cp values and spanned 19.8 cycles for
ACT  to 29.2 cycles for TBP. As presented in Figure 1,
expression levels of ALAS, HMBS, RPS29 and TBP were
low, with median Cp values between 28 and 30 cycles.
HPRT, KALPHA and SHAD displayed intermediate expres-
sion levels with median Cp values between 23 and 26
cycles. In contrast, high expression of ACT, B2M, GAPDH,
RPS18 and RPL27 was detected, with Cp values between
19 and 22 cycles. Among the 12 genes, the maximum and
minimum expression range was 10.4 cycles for KALPHA
and 5.8 for GAPDH, respectively.
Reference gene expression stability in the pool of HNSCC 
plus normal mucosa samples
We first studied the inter-sample stability of reference
gene expression in the pool of HNSCC plus normal
mucosa samples. Using geNorm software, we found that
M values for all 12 studied genes were falling below the
1.5 threshold, under which a gene is considered suitable
for normalization by this program. The best combination
of two genes for normalization was GAPDH with SHAD,
an association that reached a 0.722 M value. As presented
in Figure 2, when samples were considered independently
using the NormFinder software, we found exactly the
same ranking as with geNorm. When tumor and normal
tissues were taken into consideration using the
NormFinder pairing option, we observed slight modifica-
tions in gene stability ranking, but GAPDH and SHAD
remained the two best single normalization genes and
their association was still the best combination of two
genes, with a 0.066 stability value.
Reference gene expression stability in HNSCC and normal 
mucosa separately
We then applied stability tests to HNSCC and normal
samples separately in order to identify differences with the
whole sample group. In both types of tissue, M values pro-
vided by geNorm were still under the 1.5 cut-off for the 12BMC Molecular Biology 2009, 10:78 http://www.biomedcentral.com/1471-2199/10/78
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genes. Interestingly, the four best normalization genes in
both groups given by geNorm as well as NormFinder were
ALAS, GAPDH, RPS18 and  SHAD. Similarly, the four
worst genes were ACT, KALPHA, RPL27 and RPS29. In the
HNSCC group, the best combination of two genes was
GAPDH and SHAD with an M value of 0.732. In the nor-
mal mucosa group, the best combination of two genes
was GAPDH and RPS18 with an M value of 0.654, fol-
lowed by GAPDH and SHAD with an M value of 0.709.
Reference gene expression stability in HNSCC subgroups: 
T and N Stage
More variable results were observed when stability tests
were applied to HNSCC subgroups. In the T stage sub-
group, both geNorm and NormFinder found KALPHA
and TBP to be the two most stable genes for normaliza-
tion of T1T2 tumors, while RPL27 and SHAD were the
most stable for T3T4 tumors. In the N stage subgroup,
both geNorm and NormFinder found KALPHA and SHAD
to be the two most stable genes for N0 tumors and ALAS
and TBP for N+ tumors. It is worth noting that RPL27 was
considered by geNorm as unsuitable for normalization in
T1T2 and N0 HNSCC subgroups, with an M value >1.5.
Reference gene expression compared in HNSCC and 
normal matched mucosa
As geNorm and NormFinder are not able to address the
specific issue of inter-group comparison, we statistically
evaluated the relative expression levels in HNSCC and
normal matched tissue for the 46 patients. As presented in
Table 1, relative mRNA expression levels were signifi-
cantly higher in tumors than in normal samples for B2M,
GAPDH, HMBS, HPRT, KALPHA, RPS18 and TBP (Wil-
coxon test for paired data, p < 0.001). These expression
levels were lower in tumor than in normal samples for
ACT and RPS29 (Wilcoxon test for paired data, p < 0.05).
As presented in Figure 3, it should be noted that the
median expression ratio between tumor tissue and
matched normal mucosa was very low with a maximum
over-expression of 1.4-fold for ACT and RPS29 and a max-
imum expression decrease of 1.7-fold for GAPDH  and
HPRT.
mRNA expression of 12 reference genes in HNSCC tissue and matched normal mucosa Figure 1
mRNA expression of 12 reference genes in HNSCC tissue and matched normal mucosa. Raw Cp values are rep-
resented for each gene by a box-plot. The central box represents the interquartile interval, the red line inside the box is the 
median value, and the extreme values represent the minimum and maximum values. Cp (Crossing point).
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Comparison of reference gene expression in T1T2 and 
T3T4, and N0 and N+ HNSCC
The relative expression levels of the 12 genes were com-
pared between T1T2 and T3T4 and between N0 and N+
HNSCC. No significant difference was shown between
these tumor subgroups (Wilcoxon test, p > 0.05).
Evaluation of the robustness of geNorm results by 
bootstrap technique
We bootstrapped the geNorm results to assess their
robustness (M value, ranking and 1.5 suitability thresh-
old).
For the ranking, the bootstrap results were consistent with
those of the original data set. As presented in Table 2,
SHAD was ranked the first or second most stable gene in
83% of the 10,000 generated bootstrap samples. GAPDH
remained the second most stable gene with a ranking of
second or third in 56% of the cases. It should be noted
that the ranking of some genes was highly affected by the
bootstrap procedure. For instance, RPL27 was ranked the
second most stable gene in 15% of the cases, but it was
also ranked twelfth and the least stable gene in 38% of the
cases. These results underscore the fact that gene ranking
is not an absolute means to select the most stable gene,
particularly when stability results are not very different,
which was the case for our set of 12 genes.
We observed that median M values (based on the 10,000
iterations) were falling under the 1.5 threshold for all 12
genes. Surprisingly, RPL27 (one of the least stable genes)
had the best median M value (M = 0.994), whereas SHAD
(one of the most stable genes) had one of the worst
median M value (M = 1.257). We thus decided to analyze
geNorm and NormFinder stability values of 12 reference genes in 46 HNSCC and normal matched mucosa Figure 2
geNorm and NormFinder stability values of 12 reference genes in 46 HNSCC and normal matched mucosa. 
Upper line with rhombus = stability values from geNorm; Lower line with triangles = stability values from NormFinder.
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Expression ratio between HNSCC tissue and normal mucosa in the 12 reference genes Figure 3
Expression ratio between HNSCC tissue and normal mucosa in the 12 reference genes. For estimation of the indi-
vidual expression of each gene, the expression ratios of paired tissue specimens were calculated (R = HNSCC/normal). The log 
distribution of these ratios is represented for each gene by a box-plot. The central box represents the interquartile interval, 
the white line inside the box is the median value, and the extreme values represent the minimum and the maximum.
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Table 1: Differential expression of candidate reference genes in HNSCC tissue and matched normal mucosa (46 patients)
Normal tissue HNSCC tissue
Gene Median Min Max Median Min Max P value
ACT 2.302 0.029 8.642 1.466 0.151 27.537 <0.001
ALAS 2.407 0.065 8.106 2.426 0.083 14.561 0.623
B2M 1.384 0.062 7.521 2.148 0.112 11.168 0.038
GADPH 2.087 0.368 5.070 2.948 0.145 17.192 <0.001
HMBS 1.944 0.045 5.278 1.989 0.238 10.071 0.043
HPRT 1.365 0.037 3.708 2.316 0.102 18.128 <0.001
KALPHA 1.590 0.020 5.908 3.174 0.095 17.656 <0.001
RPS18 2.207 0.258 12.132 2.690 0.093 21.544 0.039
RPL27 2.112 0.022 8.797 2.027 0.228 23.993 0.140
RPS29 2.875 0.090 22.910 2.362 0.020 18.233 0.015
SHAD 1.612 0.064 4.218 1.723 0.074 13.097 0.939
TBP 1.466 0.151 27.537 1.645 0.224 7.052 0.010
Median, minimum and maximum relative gene expression ratios of 12 reference genes in HNSCC tissue versus normal tissue are presented with 
corresponding p-values (Wilcoxon test for paired data). Rescaled values provided by qBase software are presented.BMC Molecular Biology 2009, 10:78 http://www.biomedcentral.com/1471-2199/10/78
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whether some genes presented M values above the 1.5 cut-
off value in some of the 10,000 bootstrap geNorm results.
RPS 29, TBP, HPRT, SHAD, ACT and KALPHA exhibited
M values above this stability threshold in respectively 1%,
5%, 10%, 13%, 15% and 30% of the cases.
Discussion
The measurement by RT-qPCR of quantitative transcrip-
tional differences between several physiological or patho-
logical conditions is of great interest for clinical
applications. The major challenge of this mRNA quantiza-
tion is the variability introduced at each step of the proce-
dure by experimental errors or approximation and by
variable enzymatic activity. To date, the most commonly
used strategy to deal with this problem has been the nor-
malization of raw data by at least one internal reference
gene, so-called reference gene [3,7,8]. The pitfall of this
approach is that no universal reference gene exists since
many of them are regulated in several conditions, which
may lead to altered findings and wrong experimental con-
clusions. It has been emphasized that researchers need to
choose the most appropriate reference gene for a given tis-
sue or disease, and should therefore prove the suitability
of these genes in each specific experimental situation
[12,13].
In the field of HNSCC, this study is the first one that
aimed to select suitable reference genes for the normaliza-
tion of RT-qPCR studies based on the analysis of human
tissue. A similar approach was employed in other types of
cancer (breast, colon, bladder, kidney, prostate), but the
present work is particularly notable for the number of
selected genes, number of paired samples, rigorous qual-
ity control and biostatistical analyses [9,14-19].
Two parameters are key to evaluating the expression sta-
bility of reference genes: inter-sample stability and inter-
group stability [15,20,21].
First, we assessed the theoretical inter-sample expression
stability of the 12 studied genes using two popular, dedi-
cated software programs: geNorm and NormFinder. We
used this approach for the sample group treated as a
whole, as well as for the clinically relevant subgroups
(tumor tissue, normal mucosa, T1T2 stage, T3T4 stage, N0
stage, N+ stage), since quantitative expression studies fre-
quently include one of these subgroups to address specific
clinical issues. We found that the 12 candidate genes
could be considered as stable enough for normalization
purposes, except for RPL27 in T1T2 or N0 stage tumors.
Moreover, the results given by both software programs
were highly comparable. Although the stability values
were very close, some of the 12 genes appeared to be more
stable than others and should probably be used as a prior-
ity (ALAS, GAPDH, RPS18 and SHAD). Previous data sug-
gested that at least two reference genes should be
associated for accurate normalization [11], and our results
clearly showed that indeed, the association of two genes
dramatically improved the stability values, and that
GAPDH-SHAD  appeared to be the best association for
HNSCC studies.
In the literature, more or less sophisticated strategies have
been proposed to assess the inter-sample expression sta-
bility of reference genes [11,20,22]. Since no universal ref-
erence point is available, these methods are all based on
averaged cross-comparisons of the expression level of all
genes in all measured samples. This principle is certainly
relevant but has its own limitations. Indeed, the results
greatly depend on the choice of sample and on the genes
introduced into the analyses. Moreover, the reliability of
results provided by geNorm and NormFinder is question-
able, notably because these programs do not include a sta-
tistical evaluation of these results. We thus decided to
bootstrap the results of geNorm, in order to test their
robustness [23,24]. Although the bootstrap results were
globally consistent with the original data set, this statisti-
Table 2: Ranking of the 12 candidate genes after geNorm bootstrap.
Rank SHAD GAPDH ALAS RPS18 TBP HMBS HPRT B2M Kalpha ACT RPL27 RPS29
1 5 9 2 > 1> 1 1 6 1 1 00> 1> 18 0
2 24 22 13 4 8 7 >1 0 4 >1 14 0
3 83 3 1 6 1 4 6 6 > 1 > 1 4 1 8 0
4 51 8 2 0 3 1 7 6 1 > 1 3 1 3 0
5 2 1 1 1 8 3 3 8 1 08 142 > 10
6 1 7 13 13 9 15 24 6 6 4 >1 0
7 >1 4 8 2 8 16 27 19 7 6 0 >1
8 >1 1 5 >1 10 17 19 28 8 8 0 >1
9 >1 >1 2 >1 7 7 13 20 24 14 2 7
10 0 0 >1 0 9 2 5 18 21 27 4 11
11 0 0 >1 0 5 >1 >1 7 12 18 18 38
12 000 0 1 0 0 0 2 1 4 3 8 4 3
Total 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
This table presents for each gene the frequencies (in percentage) of ranking between the first and the twelfth position for the 10,000 iterations of 
geNorm bootstrap.BMC Molecular Biology 2009, 10:78 http://www.biomedcentral.com/1471-2199/10/78
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cal procedure confirmed that stability values and gene
ranking are highly altered by some changes in the original
dataset. Moreover, Lyng et al and Andersen et al empha-
sized that, for a given gene, the stability values reported by
geNorm or NormFinder depend on the genes with which
it is compared, and that co-regulations could lead to
falsely good stability results [9,20]. Thus, results provided
by these software programs should be considered as
trends and should probably not be generalized without
proper validation.
Second, we tested the inter-group stability by looking at
possible differential regulation of our 12 candidates
between clinically relevant subgroups: HNSCC versus
normal matched mucosa, T1T2 versus T3T4 and N0 versus
N+. Theoretically, the expression level of a reference gene
should not be influenced by the experimental conditions,
and some authors consider such regulated genes as irrele-
vant for normalization [15]. In our study, we found that
nine out of 12 reference genes were differentially
expressed between HNSCC and normal mucosa. This
result was not in accordance with the good stability values
obtained not only with geNorm but also with
NormFinder, which is supposed to take into considera-
tion the inter-group comparison. To resolve this ambigu-
ity, a distinction between statistically and clinically
different expressions should be made. We think that a reg-
ulated gene can be used as a reference gene for normaliza-
tion, depending on the resolution of the assay.
Statistically, regulated reference genes are acceptable for
normalization if the magnitude of this regulation is clini-
cally lower than the clinically relevant regulation that is to
be measured. For instance, in this study we observed very
weak regulations (maximum 1.7-fold) that were statisti-
cally significant. From a clinical point of view, these regu-
lations are not actually significant, since most RT-qPCR
studies require the detection of at least ten-fold expression
differences for clinical applicability Like Huggett et al. and
Toegel et al., we recommend the search for reference gene
regulations and specification of their magnitude for any
expression comparison between two sample groups
[4,13]. Once the variation of the reference gene is known,
the resolution of the RT-qPCR assay can be determined.
Inversely, the choice of reference gene can be determined
by the degree of resolution required for the assay. If the
goal of a RT-qPCR study is to detect global gene expres-
sion differences between two groups, a 1 Log systematic
bias introduced by the use of a regulated reference gene is
not recommended, but does not preclude the detection of
2 Log regulation of a gene of interest. If the goal is to pre-
cisely measure the magnitude of gene expression differ-
ence between two groups, even faintly regulated genes
should be avoided for normalization.
Conclusion
Today, a rational basis for choosing reference genes is
needed for quantitative expression studies. Here, we
present the first study that analyzes the suitability of 12
reference genes in the field of HNSCC. This study offers a
large choice of suitable reference genes, among which
research teams can choose depending on the specific set-
ting of their experiments.
In tumor tissue and/or normal mucosa, the four best nor-
malization genes are ALAS, GAPDH, RPS18 and SHAD
and the most stable combination of two genes is GAPDH-
SHAD.  KALPHA-TBP  is recommended for the study of
T1T2 tumors, RPL27-SHAD for T3T4 tumors, KALPHA-
SHAD for N0 tumors and ALAS-TBP for N+ tumors.
ACT, B2M, GAPDH, HMBS, HPRT, KALPHA, RPS18,
RPS29  and  TBP  are slightly misregulated (<1.7-fold)
between tumor and normal mucosa. Nonetheless, they
can be used for normalization depending on the resolu-
tion required for the assay.
Methods
Patients and sample collection
This study was approved by the local ethics committee.
Matched pairs of malignant and non-malignant tissue
samples were obtained from 46 patients with primary
untreated HNSCC, who gave informed consent. All
patients were Caucasian and heavy smokers and drinkers.
Patient and tumor characteristics are presented in Table 3.
Tissue samples were collected by biopsy during diagnostic
endoscopy between April 2005 and April 2007 and were
immediately snap frozen and stored in liquid nitrogen (-
180°C). The matched non-malignant tissue was collected
on the same anatomical site, as far as possible from the
primary lesion for tumors crossing the midline and on the
opposite side for well-lateralized tumors.
RNA isolation, quality control and cDNA synthesis
To obtain homogeneous and histologically well-charac-
terized samples for RNA analyses, tissue samples were cut
with a cryo-microtome into 50200 slices of 9 μm thick-
ness in RNase-free conditions. At least three frozen slices
taken from the sample core were mounted on glass slides
and briefly stained with eosine-hematoxylin for his-
topathological examination. An experienced pathologist
(H.C.) determined the non-malignant or malignant
nature of the tissue and specified its composition. HNSCC
samples with less than 30% tumor cells were excluded
from the study. In addition, normal tissues were control-
led and had to be composed of both stroma and its sur-
rounding normal epithelial layer, with no tumor cells toBMC Molecular Biology 2009, 10:78 http://www.biomedcentral.com/1471-2199/10/78
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be included in the study. Total RNA was extracted from
the remaining tissue slices using an RNeasy Mini Kit (Qia-
gen, Courtaboeuf, France), following the manufacturer's
instructions. RNA quality control and quantification were
carried out on an Agilent 2100 Bioanalyzer using Total
RNA Nano II Chips (Agilent Technologies, Massy,
France). Tissue samples with total RNA with RNA integrity
number (RIN) <6 or a concentration <85 ng/μl were
excluded.
Subsequently, 1 μg of total RNA was reverse-transcribed
using M-MLV reverse transcriptase and oligo dT14-16 as
primer (Applied Biosystems, Courtaboeuf, France), fol-
lowing the manufacturer's protocol. Samples were incu-
bated for 10 minutes at 65°C, cooled on ice for 5 minutes,
and incubated with reverse transcriptase for 1 hour at
37°C. Reverse transcriptase was then inactivated by heat-
ing at 95°C for 5 minutes. The resulting cDNA were even-
tually diluted 1:10 before being used as PCR template.
Quantitative real-time PCR (qPCR)
We quantified the mRNA expression of 12 reference genes
by real-time RT-PCR using a SYBR Green approach (Light-
Cycler Fast DNA MasterPlus SYBR Green kit) on a Light-
Cycler 480 (Roche, Meylan, France). Stringent primer sets
were designed for the 12 reference genes using Oligo 6
Software (MBI, Cascade, CO, USA). To avoid false detec-
tion of genomic DNA, although DNase was included in
the extraction procedure, amplification was done on
spliced regions of the genes. Gene references and primer
characteristics are listed in Table 4. For each qPCR reac-
tion, we used 2 μl of the diluted cDNA, 2 μl of 10 μmol.l-
1 forward and reverse primer mix, 5 μl LightCycler Fast
Table 3: Characteristics of gene-specific qPCR assays
Gene name
(synonym)
Genebank Access n°
Gene ID
Gene location Primer sequence 5'-3' Amplicon size PCR efficiency
ACTB
actin, beta
NM_001101
60
7p15-p12 f: tggctggggtgttgaaggtct
r: agcacggcatcgtcaccaact
238 1.98
ALAS1
aminolevulinate delta synthase 1, transcript 
variant 1
NM_000688
211
3p21.1 f: aacttgccaaaatctgtttc
r: ggtgatgagggagtctgaat
159 1.99
B2M
beta-2-microglobulin
NM_004048
567
15q21-q22.2 f: cagcgtactccaaagattca
r: gaatgctccactttttcaat
240 1.95
GAPDH
glyceraldehyde-3-phosphate dehydrogenase
NM_002046
2597
12p13 f: tgaacgggaagctcactgg
r: tccaccaccctgttgctgta
307 1.90
HMBS
hydroxymethylbilane synthase, transcript 
variant 1
NM_000190
3145
11q23.3 f: gaaagacaacagcatcatgag
r: accaaggagcttgaacatgc
145 1.98
HPRT1
hypoxanthine phosphoribosyltransferase 1
NM_000194
3215
Xq26.1 f: ctgacctgctggattaca
r: gcgaccttgaccatcttt
256 1.90
K-ALPHA
tuba1a, tubulin
NM_006082
10376
12q13.12 f: cagatgccaagtgacaagac
r: tccaacacaaggtcaatgat
257 1.94
RPL27
ribosomal protein L27
NM_000988
6155
17q21.1-q21.2 f: tcgccaagagatcaaagataa
r: ctgaagacatccttattgacg
121 1.94
RPS18
ribosomal protein S18
NM_022551
6222
6p21.3 f: agcttgttgtccagaccatt
r: tgaggaaagcagacattgac
187 1.84
RPS29
ribosomal protein S29 transcript variant 2
NM_001030001
6235
14q f: gcactgctgagagcaagatg
r: ataggcagtgccaaggaaga
213 1.95
SDHA
succinate dehydrogenase complex, subunit 
A, flavoprotein
NM_004168
6389
5p15 f: agcaagctctatggagacct
r: taatcgtactcatcaatccg
200 1.80
TBP
TATA box binding protein
NM_003194
6908
6q27 f: cacgaaccacggcactgatt
r: ttttcttgctgccagtctggac
89 2.01
Table 4: Clinical features of the populations
Median Min Max
Age 56.7 41.2 77.7
Quantity Percentage %
Sex Woman 4 8.7
Men 42 91.3
Site Larynx 8 17.4
Oral cavity 8 17.4
Hypopharynx 7 15.2
Oropharynx 23 50
T Stage T1T2 12 26.1
T3T4 34 73.9
N Stage N0 18 39.1
N+ 28 60.9
M stage 04 6 1 0 0
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DNA MasterPlus SYBR Green I and 11 μl PCR Water in a
final volume of 20 μl. The PCR cycle conditions were set
as follows: preincubation for 10 minutes at 95°C fol-
lowed by 40 cycles, with each cycle including 15 seconds
at 95°C, 15 seconds at 60°C, and 15 seconds at 72°C. The
temperature transition rate was 20°C/second. A melting
curve was generated by linear heating from 50°C to 95°C
in 20 minutes with 10 fluorescence measures every 1°C.
Paired malignant and non-malignant samples were
always measured in the same run to avoid inter-run varia-
tion. One negative control with no template and one pos-
itive inter-run control were included for each gene in each
qPCR run. All measurements were done in triplicate.
Standard curves were generated on separated runs for each
gene using 5 serial dilutions (ranging from 1:1 to 1:5000)
of the cDNA sample we used as positive inter-run control.
As presented in Table 4, these curves displayed efficient
amplification (>1.8) for all genes.
Specificity was confirmed by the presence of a single peak
at the expected temperature on melting curve analyses.
Crossing point (Cp) values were automatically calculated
by the LightCycler 480 ® software using the second deriva-
tive method and were imported into qBase software, ver-
sion 1.3.5, a free program for the management and
automated analysis of qPCR data. We used qBase rescaled
values for quantitative analyses [25]. Specific gene ampli-
fication efficiencies were calculated by qBase from stand-
ard curve results and were used in the quantification
algorithm. For each gene the inter-assay coefficient of var-
iation in Cp values was <9%.
Expression stability assessment
We tested the stability of the 12 reference genes by using
geNorm version 3.4 and NormFinder version 0.953.
These two dedicated software programs, freely available
on the internet, are the two most cited tools in the litera-
ture for stability assessment of reference genes. The
geNorm algorithm calculates a gene expression stability
measure M for a reference gene based on the average pair-
wise variation for that gene with all other tested reference
genes [11]. It ranks the stability of candidate genes and
gives the most stable combination of two genes. The
NormFinder algorithm relies on a model-based estima-
tion variance approach to estimate the overall expression
variation of the candidate reference genes, as well as the
variation between sample subgroups of the sample set
[20], e.g., normal versus cancer samples.
Statistical analysis
S-Plus 2000 software was used to perform the statistical
analyses. The quantitative variables were described by
median, minimum and maximum values and the qualita-
tive variables were described by frequencies and percent-
ages. The mRNA expression levels of the 12 reference
genes were compared for HNSCC tissue versus normal
matched mucosa using a Wilcoxon test for paired data
[21]. The Wilcoxon test for unpaired data was used for the
expression comparison of T1T2 versus T2T3 stages and N0
versus N+ stage. Comparisons were considered significant
if p < 0.05. Using a Visual Basic application, we boot-
strapped the results provided by geNorm on 10,000 resa-
mpled data sets (by random drawing with replacement)
extracted from the original set of 96 tissue samples
(HNSCC plus normal mucosa) [23].
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